Skip to main content
Psych Congress  

Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin

Authors  

Marlene Freeman, MD – Massachusetts General Hospital/Harvard Medical School; Maurizio Fava, MD – Massachusetts General Hospital/Harvard Medical School; Bryan Dirks, MD, MSc, MBA – ACADIA Pharmaceuticals Inc.; Manish Jha, MBBS – Icahn School of Medicine at Mt Sinai; George Papakostas, MD – Massachusetts General Hospital/Harvard Medical School; Richard Shelton, MD – University of Alabama at Birmingham; Michael Thase, MD – University of Pennsylvania Perelman School of Medicine; Madhukar Trivedi, MD – University of Texas Southwestern Medical Center; Keith Liu, PhD – ACADIA Pharmaceuticals Inc.; Srdjan Stankovic, MD, MSPH – ACADIA Pharmaceuticals Inc.

Sponsor  
Acadia Pharmaceuticals Inc.

Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY trial recently demonstrated the efficacy of adjunctive pimavanserin (PIM) for MDD when added to ongoing selective serotonin or serotonin–norepinephrine reuptake inhibitor (SSRI/SNRI) treatment. No new safety observations were reported in this study. This post-hoc analysis examines the potential impact of PIM treatment on sexual function. Study methodology has been presented previously (APA 2019). Adult male and female patients with moderate-to-severe MDD were randomized to PIM 34 mg/day (n=51) or placebo (PBO, n=152) added to ongoing SSRI/SNRI treatment. Massachusetts General Hospital–Sexual Functioning Inventory (MGH-SFI) and Hamilton Depression Rating Scale, 17-item version (HAMD-17) item 14 (sexual interest) scores were examined by analysis of covariance. Adjunctive PIM resulted in significantly greater 5-week reduction (improvement) relative to SSRI/SNRI treatment plus placebo on mean MGH-SFI scores (difference –0.634, SE 0.167; P < 0.001; effect size [ES], Cohen’s d 0.614). Similarly, PIM resulted in greater improvement compared with placebo on individual MGH-SFI items that applied to both males and females: Interest in Sex (P=0.006; ES=0.483), Ability to Get Sexually Aroused/Excited (P=0.001; ES=0.560), Ability to Achieve Orgasm (P < 0.001; ES=0.609), Overall Sexual Satisfaction (P=0.003; ES=0.524). HAMD-17 item 14 scores were also significantly more reduced (improved) with PIM (P < 0.001; ES=0.574). These results underscore the potential of adjunctive PIM for improving sexual function in patients with MDD and inadequate response to SSRIs/SNRIs. Potential benefits should be confirmed in further studies.

This poster was presented at the 32nd annual Psych Congress, held Oct. 3-6, 2019, in San Diego, California.

Back to Top